Ataxia telangiectasia and Rad3-related inhibitors and cancer therapy: where we stand

Overview of attention for article published in Journal of Hematology & Oncology, April 2019

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (89th percentile)
Good Attention Score compared to outputs of the same age and source (75th percentile)

Mentioned by

news: 2 news outlets
twitter: 2 X users

patent: 2 patents

Citations

dimensions_citation: 105 Dimensions

Readers on

mendeley: 169 Mendeley

Summary News X Patents Dimensions citations

So far, Altmetric has seen 2 patents that reference this research output.

USE OF SODIUM TRANS-[TETRACHLORIDOBIS(1H-INDAZOLE)RUTHENATE(III)] FOR TREATING CANCERS

Application WO-2022104470-A1

World Intellectual Property Organisation (WIPO)

ATR INHIBITORS FOR THE TREATMENT OF CANCER

Application WO-2021228758-A1

World Intellectual Property Organisation (WIPO)

This page shows the most recent patents that mention this research output.

Click here to find out how to access more activity.